TY - JOUR
T1 - CLL-506 Clinical Outcomes Beyond Progression on Ibrutinib in Patients With Chronic Lymphocytic Leukemia
AU - Hampel, Paul
AU - Rabe, Kari
AU - Call, Timothy
AU - Ding, Wei
AU - Leis, Jose
AU - Chanan-Khan, Asher
AU - Kenderian, Saad
AU - Muchtar, Eli
AU - Wang, Yucai
AU - Ailawadhi, Sikander
AU - Koehler, Amber
AU - Parrondo, Ricardo
AU - Schwager, Susan
AU - Sher, Taimur
AU - Hanson, Curtis
AU - Shi, Min
AU - Van Dyke, Daniel
AU - Braggio, Esteban
AU - Slager, Susan
AU - Kay, Neil
AU - Parikh, Sameer
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10
Y1 - 2022/10
N2 - Context: Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. Objective: To analyze survival estimates of patients with CLL following true disease progression (per iwCLL 2018 criteria) on ibrutinib. Design: Retrospective. Setting: Academic. Patients or Other Participants: Patients with CLL who received ibrutinib therapy for CLL at a Mayo Clinic Cancer Center site (Arizona, Florida, Minnesota) between 4/2012-6/2021. Main Outcome Measures: Treatment-free survival (TFS) was analyzed as the duration from the start of treatment immediately after ibrutinib failure to the start of the subsequent line of therapy or death, whichever occurred earlier. Overall survival (OS) was analyzed as the time from date of progression while on ibrutinib and from subsequent therapy start date until date of death or last known to be alive. OS was analyzed using the Kaplan-Meier method (with comparisons of OS by characteristics analyzed by the log rank test). Results: Among 144 patients with CLL identified to have disease progression on ibrutinib, the median age was 68 years and 74% were male. Unmutated IGHV (90%) and TP53 disruption (50%) were common in evaluable patients at the time of progression on ibrutinib. The median OS for the entire cohort following progression on ibrutinib was 25.5 months; 29.8 months and 8.3 months following CLL progression (n=104) and Richter's transformation (n=38), respectively. Longer OS was observed among patients with CLL progression who had received ibrutinib in the frontline (n=23) compared to relapsed/refractory setting (not reached versus 28.5 months; p=0.04), but was similar amongst patients treated with 1, 2, or ≥3 prior lines (18.5, 30.9, and 26.0 months, respectively, p=0.24). Among patients with CLL disease progression on ibrutinib, next-line treatment with chimeric antigen receptor T-cell therapy or venetoclax-based treatment was associated with significantly longer median OS and TFS compared to other approved treatments (OS: not-reached, 29.8 months, and 9.1 months, respectively, p=0.034; TFS: 30.4 months, 20.1 months, and 4.4 months, respectively, p<0.001) Conclusions: These findings suggest an unmet need for this growing patient population while supporting the current practice of next-line venetoclax and participation in clinical trials.
AB - Context: Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. Objective: To analyze survival estimates of patients with CLL following true disease progression (per iwCLL 2018 criteria) on ibrutinib. Design: Retrospective. Setting: Academic. Patients or Other Participants: Patients with CLL who received ibrutinib therapy for CLL at a Mayo Clinic Cancer Center site (Arizona, Florida, Minnesota) between 4/2012-6/2021. Main Outcome Measures: Treatment-free survival (TFS) was analyzed as the duration from the start of treatment immediately after ibrutinib failure to the start of the subsequent line of therapy or death, whichever occurred earlier. Overall survival (OS) was analyzed as the time from date of progression while on ibrutinib and from subsequent therapy start date until date of death or last known to be alive. OS was analyzed using the Kaplan-Meier method (with comparisons of OS by characteristics analyzed by the log rank test). Results: Among 144 patients with CLL identified to have disease progression on ibrutinib, the median age was 68 years and 74% were male. Unmutated IGHV (90%) and TP53 disruption (50%) were common in evaluable patients at the time of progression on ibrutinib. The median OS for the entire cohort following progression on ibrutinib was 25.5 months; 29.8 months and 8.3 months following CLL progression (n=104) and Richter's transformation (n=38), respectively. Longer OS was observed among patients with CLL progression who had received ibrutinib in the frontline (n=23) compared to relapsed/refractory setting (not reached versus 28.5 months; p=0.04), but was similar amongst patients treated with 1, 2, or ≥3 prior lines (18.5, 30.9, and 26.0 months, respectively, p=0.24). Among patients with CLL disease progression on ibrutinib, next-line treatment with chimeric antigen receptor T-cell therapy or venetoclax-based treatment was associated with significantly longer median OS and TFS compared to other approved treatments (OS: not-reached, 29.8 months, and 9.1 months, respectively, p=0.034; TFS: 30.4 months, 20.1 months, and 4.4 months, respectively, p<0.001) Conclusions: These findings suggest an unmet need for this growing patient population while supporting the current practice of next-line venetoclax and participation in clinical trials.
KW - B-cell chronic lymphocytic leukemia
KW - CLL
KW - ibrutinib
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85138191537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138191537&partnerID=8YFLogxK
U2 - 10.1016/S2152-2650(22)01351-9
DO - 10.1016/S2152-2650(22)01351-9
M3 - Article
C2 - 36163897
AN - SCOPUS:85138191537
SN - 2152-2650
VL - 22
SP - S281
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
ER -